|By Marketwired .||
|July 25, 2014 08:00 AM EDT||
TOKYO, JAPAN -- (Marketwired) -- 07/25/14 -- REGiMMUNE Corporation, a biotechnology company focused on the development of immune regulatory therapeutics with its reVax technology, announced that it will present results from its research on its novel approach to long-term tolerance in organ transplantation without continuous administration of immune suppressants at the World Transplant Congress (WTC) on Tuesday, July 29. The poster, "A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade," will be presented by Toshihito Hirai, MD, Department of Urology, Tokyo Women's Medical University, Tokyo. The WTC acknowledged the importance of REGiMMUNE's research by designating it as one of the top 100 papers submitted (or top 3%) for presentation at this international meeting.
Robust, lifelong, donor-specific tolerance can be reliably achieved by induction of mixed chimerism in various animal models of bone transplantation. To date, the clinical application of these protocols has been impeded by the potential toxicity of the required host conditioning regimens. The REGiMMUNE poster presents the potential of a novel approach using a ligand alpha-GalCer (aGC) for iNKT cells and suboptimal dosage of antibody that blocks CD40:CD40L signaling as a powerful method to generate mixed chimerism. The data suggest a new insight -- that the immune direction of iNKT cells is controlled through a type of APC presenting a-GalCer and costimulation signals, and that it is possible to enhance the innate ability of immune tolerance by appropriate activation of iNKT cells.
REGiMMUNE chief executive officer Yasuyuki Ishii, PhD, commented, "As described in our poster presentation, this combination therapy of aGC liposome with CD40/40L blockade offers great promise and another approach to induce solid organ transplant tolerance -- without continuous administration of immune suppressants -- that may be long lasting."
Abstract: "A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Co-stimulatory Blockade"
Invariant natural killer T (iNKT) cells are one of the innate lymphocytes that regulate immunity, although it is still elusive how iNKT cells should be manipulated for transplant tolerance. We previously reported that the liposomal formulation of a-galactosylceramide (Lipo-aGC ) could enhance immune-regulative aspect of iNKT cells compared to the conventional aGC. Here we describe a novel approach to induce mixed chimerism (MC ) by activating iNKT cells with Lipo-aGC under CD40-CD40L blockade (MR1). 3Gy irradiated BALB/c mice were transplanted with B6 bone marrow cells (BMC s) with/without Lipo-aGC and/or several dosages of MR1. Only combination therapy of Lipo-aGC plus suboptimal-MR1 showed robust MC. Mice established MC completely accepted subsequent cardiac allografts in a donor-specific manner. High amounts of Th2-cytokines were detected right after iNKT-cell activation, while subsequent IFN-γ production by NK cells was effectively inhibited by MR1. Expansion of regulatory T cells (Tregs) was observed in MC mice and Treg-depletion on 1 day before transplantation resulted MC brake. Further, iNKT-cell knockout mice failed both MC establishment and Tregs expansion. These results collectively suggest that our new protocol makes it possible to induce donor-specific tolerance by enhancement of the innate regulatory mechanism in place of the conventional immunosuppression.
Oral Abstract Session: "Tolerance/Immune Deviation"
Date: Tuesday, 7-29-2014
Time: 11:15 am - 12:45 pm
Publication Number: 1415
Presentation Time: 11:51 am
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The company's proprietary platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. Using its reVax technology, REGiMMUNE is developing RGI-2001, which may be the first drug in the class of Treg-inducing agents.
The company is also applying its reVax technology to develop a range of pipeline products, including its RGI-1000 series for allergy and its RGI-3100 series for type 1 diabetes. Additionally REGiMMUNE is developing products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company is seeking pharmaceutical partnership opportunities for its products worldwide, exclusive of Japan. REGiMMUNE is headquartered in Tokyo, Japan and has a US operation in San Francisco, California. For more information, visit www.regimmune.com.
Oct. 6, 2015 05:00 PM EDT Reads: 215
Oct. 6, 2015 05:00 PM EDT Reads: 243
Oct. 6, 2015 04:45 PM EDT Reads: 318
SYS-CON Events announced today that Cloud Raxak has been named “Media & Session Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Raxak Protect automates security compliance across private and public clouds. Using the SaaS tool or managed service, developers can deploy cloud apps quickly, cost-effectively, and without error.
Oct. 6, 2015 04:40 PM EDT
Oct. 6, 2015 04:00 PM EDT Reads: 299
Oct. 6, 2015 03:00 PM EDT Reads: 106
Oct. 6, 2015 02:45 PM EDT Reads: 363
Oct. 6, 2015 02:00 PM EDT Reads: 222
Oct. 6, 2015 01:00 PM EDT Reads: 580
Oct. 6, 2015 01:00 PM EDT Reads: 734
Oct. 6, 2015 12:45 PM EDT Reads: 456
Oct. 6, 2015 12:30 PM EDT Reads: 575
Oct. 6, 2015 12:15 PM EDT Reads: 102
Organizations already struggle with the simple collection of data resulting from the proliferation of IoT, lacking the right infrastructure to manage it. They can't only rely on the cloud to collect and utilize this data because many applications still require dedicated infrastructure for security, redundancy, performance, etc. In his session at 17th Cloud Expo, Emil Sayegh, CEO of Codero Hosting, will discuss how in order to resolve the inherent issues, companies need to combine dedicated a...
Oct. 6, 2015 12:00 PM EDT Reads: 436
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Oct. 6, 2015 12:00 PM EDT Reads: 283